SCHEMBL20122571

SCHEMBL20122571

CC(=O)OCOC(=O)SC[C@H](NC(=O)C(C)(C)S)C(=O)Oc1ccccc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ACE P12821 3/20 0.41
▸ MME P08473 1/20 0.41
▸ ACE2 Q9BYF1 1/20 0.41
▸ ATM Q13315 1/20 0.36
▸ L3MBTL1 Q9Y468 1/20 0.36
▸ NFKB1 P19838 1/20 0.35
▸ NFKB2 Q00653 1/20 0.35
▸ RELA Q04206 1/20 0.35
▸ IDO1 P14902 1/20 0.32
▸ THRB P10828 1/20 0.32
▸ TDP1 Q9NUW8 1/20 0.32
▸ CYP1A2 P05177 2/20 0.32
▸ MTNR1A P48039 3/20 0.31
▸ MTNR1B P49286 3/20 0.31
▸ GAA P10253 2/20 0.30
▸ ALDH1A1 P00352 2/20 0.30
▸ HSP90AA1 P07900 1/20 0.30
▸ MAPT P10636 1/20 0.30
▸ MEN1 O00255 1/20 0.30
▸ CYP3A4 P08684 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20122375 0.91 ACE (0.41) ACEMMEACE2ATML3MBTL1
SCHEMBL20122476 0.90 ACE (0.40) ACEMMEACE2ATML3MBTL1
SCHEMBL20122402 0.88 ATM (0.36) ATML3MBTL1NFKB1NFKB2RELA
SCHEMBL20122544 0.86 MME (0.43) ACEMMEACE2IDO1CYP1A2
SCHEMBL20122543 0.84 MME (0.33) ACEMMEACE2CYP1A2CYP2C9
SCHEMBL20122586 0.83 ACE (0.40) ACEMMEACE2NFKB1THRB
SCHEMBL20122567 0.83 MME (0.33) ACEMMEACE2
SCHEMBL20122569 0.81 CYP1A2 (0.33) ACEMMEACE2CYP1A2CYP2C9
SCHEMBL20122568 0.81 CYP1A2 (0.38) ACEMMEACE2L3MBTL1CYP1A2
SCHEMBL20122570 0.80 MME (0.31) ACEMMEACE2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9963428-B1 Bucillamine prodrugs, pharmaceutical compositions thereof, and methods of use Nguyen, Mark Quang (US) 2018-05-08 — — US disclosed
Send feedback